One Clever Macrophage Checkpoint
- 1 June 2019
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 25 (11) , 3202-3204
Abstract
Macrophages are a key component of the tumor microenvironment (TME). Blocking Clever-1, a molecule expressed in M2-like macrophages, unleashed macrophage and T-cell–mediated antitumor immunity. Myeloid checkpoints including Clever-1 hold promise as alternative or complementary immunotherapy strategies. See related article by Viitala et al., p. 3289Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (IG 19014, 1000 9962, 21147,, IG 20269)
This publication has 5 references indexed in Scilit:
- The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell–mediated resistance to metastasisNature Immunology, 2019
- Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T-cell Response against Immunosuppressive TumorsClinical Cancer Research, 2019
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s LymphomaNew England Journal of Medicine, 2018
- Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trialThe Lancet, 2017
- Tumour-associated macrophages as treatment targets in oncologyNature Reviews Clinical Oncology, 2017